Virax Biolabs Group Limited

NasdaqCM VRAX

Virax Biolabs Group Limited Market Capitalization on January 14, 2025: USD 9.94 M

Virax Biolabs Group Limited Market Capitalization is USD 9.94 M on January 14, 2025, a 176.95% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.
  • Virax Biolabs Group Limited 52-week high Market Capitalization is USD 32.03 M on August 21, 2024, which is 222.16% above the current Market Capitalization.
  • Virax Biolabs Group Limited 52-week low Market Capitalization is USD 2.11 M on May 02, 2024, which is -78.82% below the current Market Capitalization.
  • Virax Biolabs Group Limited average Market Capitalization for the last 52 weeks is USD 6.67 M.
Key data
Date Market Capitalization Share Price Price to Earnings Ratio (P/E) Price to Sales Ratio (P/S)
Market news
Loading...
NasdaqCM: VRAX

Virax Biolabs Group Limited

CEO Mr. James Foster
IPO Date July 21, 2022
Location United Kingdom
Headquarters 30 Broadwick Street
Employees 17
Sector Health Care
Industries
Description

Virax Biolabs Group Limited, a biotechnology company, sells, distributes, and markets diagnostics test kits, and med-tech and PPE products for the prevention, detection, diagnosis, and risk management of viral diseases in the field of immunology. The company provides rapid antibody IgC/IgM tests, antigen tests, polymerase chain reaction rapid tests, and neutralizing antibody tests under the ViraxClear brand name; and med-tech and PPE products, such as employee protection equipment products under the ViraxCare brand name, as well as infrared thermometers, pulse oximeters, masks, gloves, and other PPE products. It also distributes nebulizing machines and smart wearable devices that alert employees to help them follow social distance guidelines. In addition, the company operates an online platform that sells ViraxClear and ViraxCare products. It serves clinics, pharmacies, laboratories, hospitals, and other groups, as well as corporations, employees, individual consumers, hospital systems, and public and private institutions. The company operates in Europe, South America, the Asia Pacific, Sub-Saharan Africa, and internationally. The company was formerly known as Virax Biolabs (Cayman) Limited and changed its name to Virax Biolabs Group Limited in September 2021. Virax Biolabs Group Limited was incorporated in 2021 and is headquartered in London, the United Kingdom.

Similar companies

ALLR

Allarity Therapeutics, Inc.

USD 1.01

-5.61%

BDRX

Biodexa Pharmaceuticals Plc

USD 4.18

-2.79%

CDIO

Cardio Diagnostics Holdings, Inc.

USD 0.57

-9.14%

KPRX

Kiora Pharmaceuticals, Inc.

USD 3.21

-5.87%

StockViz Staff

January 15, 2025

Any question? Send us an email